echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Safe treatment of children's myopia Santen Pharmaceutical reached atropine preparation license agreement

    Safe treatment of children's myopia Santen Pharmaceutical reached atropine preparation license agreement

    • Last Update: 2021-08-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 10, 2021, Santen and Sydnexis announced that they have reached an exclusive license agreement for the development and promotion of Sydnexis's low-dose atropine preparation SYD-101 in Europe, the Middle East and Africa (EMEA)
    .


    SYD-101 solves the problem of the stability of low-concentration atropine in a neutral environment, and is used to treat myopia in children


    As one of the most common eye diseases, myopia is a growing public health challenge that is expected to affect 5 billion people worldwide by 2050
    .


    The increase in morbidity and disease severity is mainly due to life>


    As an inhibitor of M cholinergic receptors, atropine eye drops were originally used for mydriatic refraction
    .


    Scientists later discovered that low concentrations of atropine are effective in treating myopia


    ▲The molecular structure of atropine (photo source: Harbin, Public domain, via Wikimedia Commons)

    SYD-101 is an under-development low-dose atropine sulfate eye drops, which aims to achieve the curative effect of treating myopia in children, while enhancing the pharmacological stability and reducing discomfort, so as to improve the continuity of treatment
    .


    SYD-101 does not need to lower the pH value, and can reach a validity period of up to 3 years at room temperature


    “Children’s eye health is an important part of their overall health
    .


    As part of this agreement, we will work together to bring SYD-101 to the EMEA market,” said Mr.


    Reference materials:

    [1] Santen and Sydnexis execute an exclusive licensing agreement for SYD-101, a novel investigational treatment for progressive childhood myopia.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.